ES2129658T3 - Identificacion de ligandos mediante amplificacion selectiva de celulas transfectadas con receptores. - Google Patents

Identificacion de ligandos mediante amplificacion selectiva de celulas transfectadas con receptores.

Info

Publication number
ES2129658T3
ES2129658T3 ES94923478T ES94923478T ES2129658T3 ES 2129658 T3 ES2129658 T3 ES 2129658T3 ES 94923478 T ES94923478 T ES 94923478T ES 94923478 T ES94923478 T ES 94923478T ES 2129658 T3 ES2129658 T3 ES 2129658T3
Authority
ES
Spain
Prior art keywords
amplification
cells transfected
leagues
receptors
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923478T
Other languages
English (en)
Inventor
Mark Robert Brann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2129658T3 publication Critical patent/ES2129658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/10—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases p-Nitrophenol derivatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

UN METODO PARA DETECTAR UNA SUSTANCIA CAPAZ DE ACTUAR COMO LIGANDO, QUE CONSISTE EN: (A) INCUBAR, BAJO CONDICIONES QUE PERMITAN LA AMPLIFICACION DE LA CELULA, CELULAS TRANSFECTADAS CON UN ADN QUE CODIFICA UN RECEPTOR CAPAZ DE INFLUIR EN LA AMPLIFICACION CELULAR EN RESPUESTA A UN LIGANDO, EN DONDE LAS CELULAS INCLUYEN UN MARCADOR DE AMPLIFICACION CELULAR, CON UNA SUSTANCIA DE ENSAYO QUE ES UN AGONISTA POTENCIAL O ANTAGONISTA DEL RECEPTOR Y (B) TRAS UN PERIODO DE TIEMPO SUFICIENTE COMO PARA PERMITIR LA AMPLIFICACION CELULAR, SE DETERMINA LA PRESENCIA O AUSENCIA DE AMPLIFICACION EN LAS CELULAS QUE CONTIENEN EL MARCADOR EN RELACION A LAS CELULAS QUE NO CONTIENEN EL MARCADOR.
ES94923478T 1993-07-13 1994-07-13 Identificacion de ligandos mediante amplificacion selectiva de celulas transfectadas con receptores. Expired - Lifetime ES2129658T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9169493A 1993-07-13 1993-07-13

Publications (1)

Publication Number Publication Date
ES2129658T3 true ES2129658T3 (es) 1999-06-16

Family

ID=22229179

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923478T Expired - Lifetime ES2129658T3 (es) 1993-07-13 1994-07-13 Identificacion de ligandos mediante amplificacion selectiva de celulas transfectadas con receptores.

Country Status (13)

Country Link
US (3) US5707798A (es)
EP (1) EP0708922B1 (es)
JP (1) JP3102571B2 (es)
KR (1) KR100272459B1 (es)
AT (1) ATE177535T1 (es)
AU (1) AU679253B2 (es)
CA (1) CA2167048C (es)
DE (1) DE69417037T2 (es)
DK (1) DK0708922T3 (es)
ES (1) ES2129658T3 (es)
IL (1) IL110298A (es)
NZ (1) NZ269442A (es)
WO (1) WO1995002823A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69527585T2 (de) * 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6287850B1 (en) * 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
KR19980702511A (ko) * 1995-02-28 1998-07-15 크라우더 티 알 아테롬성 동맥경화증을 치료하기 위한 목소니딘의 용도
HUP9800353A3 (en) * 1995-03-03 2001-01-29 Syngenta Participations Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
HUP9900029A3 (en) 1995-10-10 2001-02-28 Novartis Ag Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation
US6303115B1 (en) * 1996-06-17 2001-10-16 Microcide Pharmaceuticals, Inc. Screening methods using microbial strain pools
US5985584A (en) * 1997-02-19 1999-11-16 American Cyanamid Company Method to identify plant proteins that function in G protein coupled systems and compositions therefor
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
EP1070257A2 (en) * 1998-04-06 2001-01-24 Lerner Pharmaceuticals, Inc. Directed evolution biosensors
US6277588B1 (en) * 1998-05-01 2001-08-21 Tel Aviv University Screening of cell populations
WO2000035274A1 (en) * 1998-12-17 2000-06-22 The Johns Hopkins University School Of Medicine Olfactory receptor expression libraries and methods of making and using them
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US20050148018A1 (en) * 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
WO2001038874A1 (en) * 1999-11-24 2001-05-31 Millennium Pharmaceuticals, Inc. Expression cloning method
US20030092071A1 (en) * 2000-02-01 2003-05-15 Jasna Jerecic Interaction of NMDA receptor with protein tyrosine phosphatase
CA2398250A1 (en) * 2000-02-01 2001-08-09 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
CN1401000A (zh) * 2000-02-08 2003-03-05 爱诗爱诗制药株式会社 检测配体或类配体低分子量化合物的方法
KR20080059687A (ko) * 2000-03-06 2008-06-30 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
TW200505900A (en) * 2000-04-28 2005-02-16 Acadia Pharm Inc Muscarinic agonists
CN1333213A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——细胞信号传导蛋白My D24.09和编码这种多肽的多核苷酸
US6576422B1 (en) 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US6977152B2 (en) * 2001-09-07 2005-12-20 Virtual Arrays, Inc. Biological assays using coded RNA reporters
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
KR100809569B1 (ko) 2001-10-02 2008-03-04 아카디아 파마슈티칼스 인코포레이티드 무스카린 제제로서 벤즈이미다졸리디논 유도체
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1461318B9 (en) * 2001-12-28 2005-12-28 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
CN101050215A (zh) * 2001-12-28 2007-10-10 阿卡蒂亚药品公司 作为单胺受体调节剂的螺氮杂环化合物
WO2003076897A2 (en) * 2002-03-05 2003-09-18 Vitra Bioscience, Inc. Multiplexed analysis of cellular responses using endogenous reporter genes
US7199844B2 (en) * 2002-05-28 2007-04-03 Rfstream Corporation Quadratic nyquist slope filter
WO2003104216A1 (en) * 2002-06-10 2003-12-18 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
RU2320646C2 (ru) * 2002-06-24 2008-03-27 Акадиа Фармасьютикалз Инк. N-замещенные производные пиперидина в качестве агентов серотонинового рецептора
DE10233516A1 (de) 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6884473B2 (en) * 2002-12-24 2005-04-26 Macronix International Co., Ltd. Method for fabricating metal silicide
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
BRPI0406592A (pt) * 2003-01-23 2005-12-20 Acadia Pharm Inc Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
RU2005129099A (ru) * 2003-02-19 2006-04-20 Акадиа Фармасьютикалз Инк. (Us) Комбинаторный "scaffold" подход к фармакофорам лигандов рецепторов уротензина ii и соматостатина 5 типа
BRPI0409523A (pt) * 2003-03-28 2006-04-18 Acadia Pharm Inc método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
WO2005029035A2 (en) * 2003-09-16 2005-03-31 Norak Biosciences, Inc. Methods of screening compositions for g protein-coupled receptor agonist activity
US20050136444A1 (en) * 2003-09-25 2005-06-23 Scully Audra L. Treating neuropathic pain with neuropeptide FF receptor 2 agonists
CN1875033A (zh) * 2003-11-03 2006-12-06 阿卡蒂亚药品公司 应用rap－ras嵌合蛋白对g蛋白偶联受体进行高通量功能分析
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
US7825265B2 (en) * 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US7268232B2 (en) * 2004-05-17 2007-09-11 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2530258T3 (es) * 2004-09-27 2015-02-27 Acadia Pharmaceuticals Inc. Síntesis de una forma cristalina de sal tartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida
WO2006055786A2 (en) * 2004-11-19 2006-05-26 Acadia Pharmaceuticals Inc. Methods to identify ligands of hormone nuclear receptors
CN101119993B (zh) 2005-01-10 2015-03-04 阿卡蒂亚药品公司 作为选择性雄激素受体调节剂的氨基苯基衍生物
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) * 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
EP1937677A1 (en) * 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007047776A1 (en) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Iron catalyzed cross-coupling reactions of imidoyl derivatives
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
US7655396B1 (en) 2006-09-29 2010-02-02 Allergan, Inc. Methods for detecting receptor modulator activity
AU2007334038A1 (en) 2006-12-18 2008-06-26 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
US20090082388A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
US20120196302A1 (en) * 2008-10-07 2012-08-02 Lai Lee Jene Detecting method
WO2010111353A1 (en) 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US20110150769A1 (en) * 2009-08-06 2011-06-23 Anderson David J Identification and use of compounds for treating persistent pain
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
US20140241990A1 (en) * 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
CA2903276A1 (en) 2013-03-15 2014-09-25 Acadia Pharmaceuticals, Inc. Muscarinic agonists
CA2937107C (en) 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
BR112020003477A2 (pt) 2017-08-21 2020-08-25 Acadia Pharmaceuticals, Inc. compostos e método para tratar uma doença
WO2019040105A2 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP3806839B1 (en) 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Retinoic acid receptor-beta2 agonist with cardioprotective effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
IE20020110A1 (en) * 1990-09-13 2003-05-28 Univ Duke Expression of G Protein Coupled Receptors in Yeast
CA2135644C (en) * 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy

Also Published As

Publication number Publication date
US5707798A (en) 1998-01-13
US5912132A (en) 1999-06-15
EP0708922A1 (en) 1996-05-01
WO1995002823A1 (en) 1995-01-26
US5955281A (en) 1999-09-21
DE69417037D1 (de) 1999-04-15
AU7333094A (en) 1995-02-13
JP3102571B2 (ja) 2000-10-23
CA2167048A1 (en) 1995-01-26
IL110298A (en) 1999-04-11
IL110298A0 (en) 1994-10-21
JPH09500023A (ja) 1997-01-07
DE69417037T2 (de) 1999-10-21
CA2167048C (en) 2001-09-25
AU679253B2 (en) 1997-06-26
ATE177535T1 (de) 1999-03-15
EP0708922B1 (en) 1999-03-10
KR100272459B1 (ko) 2000-11-15
NZ269442A (en) 1997-06-24
DK0708922T3 (da) 1999-09-27

Similar Documents

Publication Publication Date Title
ES2129658T3 (es) Identificacion de ligandos mediante amplificacion selectiva de celulas transfectadas con receptores.
DE69133135D1 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
ES2057571T3 (es) Receptor de pdgf-alfa.
ES2192060T3 (es) Analisis de bioluminiscencia para agonistas o antagonistas de un receptor acoplado al calcio.
BR0014106A (pt) Método em um sistema de comunicação celular para relato de resultados de medições de célula associados com células do sistema de uma estação transceptora, sistema de comunicação celular, estação móvel para utilização em um sistema de comunicação celular, e, nó de rede de um sistema de comunicação celular
AU4007401A (en) Function homology screening
GB2348702A8 (en) Antibiotic sensitivity testing
ES2119376T3 (es) Ensayo de enlace.
GB9908681D0 (en) Apparatus for, and method of, introducing a substance into an object
FR2800871B1 (fr) Procede et dispositif d'essai triaxial in situ
BR9707942A (pt) Sistema de teste para substâncias ou misturas de substâncias químicas
ES2133727T3 (es) Derivados de acido hidroxamico como inhibidores de metaloproteinasa.
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
Bovee et al. Validation and application of a robust yeast estrogen bioassay for the screening of estrogenic activity in animal feed
AR245534A1 (es) Conjunto de reactivos (kit) de aplicacion en inmunoensayos para enzimas
Milusheva et al. Release of acetylcholine and noradrenaline from the cholinergic and adrenergic afferents in rat hippocampal CA1, CA3 and dentate gyrus regions
Malhotra et al. Comparison of secretion of catecholamines from the rat adrenal medulla during continuous exposure to nicotine, muscarine or excess K
AR010041A1 (es) Agonistas multifuncionales quimericos de receptores de hematopoyetina
GB2433319A (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
NZ524693A (en) Methods for identifying VPAC receptor agonists for treating muscle atrophy using vasoactive intestinal peptide receptors
Kitazawa et al. Histamine mediates the muscle layer‐specific responses in the isolated swine myometrium
DK1185873T3 (da) Reportermolekyler og fremgangsmåde til analyse af höjspecifitetsproteaseraktivitet
ZEYTINĞOLU et al. Regulation of neurotensin release by a continuous line of mammalian C-cells: The role of biogenic amines
ES2081900T3 (es) Composiciones de ensayo de barbituratos y metodos.
Yasuno et al. Expression of steroidogenic factor 1 and pituitary specific transcription factor 1 in rat pituitary adenomas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 708922

Country of ref document: ES